Core Viewpoint - Merus has agreed to be acquired at a 41% premium following a successful trial of a cancer drug [1] Company Summary - The acquisition reflects confidence in Merus's recent positive trial results for its cancer drug, which may enhance its market position and investor interest [1] Industry Summary - The deal highlights ongoing consolidation trends in the biopharmaceutical industry, particularly in the oncology sector, as companies seek to bolster their drug pipelines through strategic acquisitions [1]

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, sources say https://t.co/8SNhwpbplv ...